Navigation Links
Collaboration between researchers yields more comprehensive portrait of brain cancer
Date:9/4/2008

Huntsville, Ala. -- A team including researchers at the HudsonAlpha Institute and Stanford University, together with colleagues from a number of other organizations, today publishes a comprehensive analysis of genomic variation in the brain cancer glioblastoma. These results are the first from the Cancer Genome Atlas (TCGA) research network, a collaborative effort funded by the National Cancer Institute and the National Human Genome Research Institute of the National Institutes of Health. Glioblastoma is the most common and most aggressive of the primary brain tumors: Notably, U.S. Senator Edward M. Kennedy was diagnosed with glioblastoma earlier this year.

Drs. Devin Absher and Rick Myers, with their labs at HudsonAlpha and Stanford, measured changes in the genetic code of both normal and cancer samples. They specifically looked at regions that either gained or lost large chunks of DNA, larger than 1000 bases, to determine the molecular differences between a normal and glioblastoma genome. The data were analyzed in collaboration with Drs. Gavin Sherlock and James Brooks at Stanford, and Dr. Jun Li at the University of Michigan.

Tumors generally accumulate gains and losses in DNA as they grow, and measuring these changes in a number of samples can illuminate which changes are necessary for tumor development. Targeting genes affected by these changes can lead to improved diagnosis and more specific therapies, with fewer side effects to normal cells in the brain.

The HudsonAlpha and Stanford data on genomic changes were integrated with data from institutions around the country measuring changes in other types of genomic variation and in epigenomic variation. Epigenomic variation refers to molecules that are added to our genome to regulate how genetic instructions are processed in the cell. We know these changes are important to cancer cells, but previous studies have not integrated genomic and epigenomic measurements on such a large scale.

According to Absher, "This is a paradigm shift in how cancer is analyzed. These comprehensive genomic and epigenomic analyses on a set of common tumors stringently assessed by research organizations across the country will ideally increase our fundamental understanding of cancer, and help us develop better diagnostic tools and treatments."

Myers added, "The excitement in this study is the integration of so many teams, taking multiple ways of measuring our genome and producing such a broad picture of cancer genetics. My laboratory at HudsonAlpha plans to continue studying cancer genetics, working with local physicians as well as our important collaborators at Stanford and Michigan."


'/>"/>

Contact: Holly Ralston McClain
hmcclain@hudsonalpha.org
256-508-8954
HudsonAlpha Institute for Biotechnology
Source:Eurekalert

Related biology news :

1. BASF and Harvard University announce extensive research collaboration
2. Safeway Inc. and PCF to fund landmark prostate cancer research collaboration
3. Conference on healthspan offers new opportunities for interdisciplinary collaboration
4. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
5. Major international collaboration offers new clues to genetics of type 2 diabetes
6. Major collaboration uncovers surprising new genetic clues to diabetes
7. Iowa State-ConocoPhillips collaboration advances 26 research projects in first year
8. US and UK research centers launch major collaboration on atmospheric research, technology
9. Gladstone scientists create Wikipathways to foster research collaboration
10. OHSU commercial collaborations have surged
11. Study shows link between alcohol consumption and hiv disease progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a medical ... (IV) therapy, today announced receipt of its ISO 13485 Certification, the ... the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early detection ... "This is an important ...
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
Breaking Biology Technology: